Oppenheimer has reaffirmed its 'Outperform' rating and a price target of $8.00 for Gain Therapeutics (NASDAQ: GANX), whose stock rose by over 10% last week, reaching $1.82. This increase comes despite a 43% drop since the start of the year. Analysts maintain a bullish consensus on the stock, with price targets ranging from $5 to $8. The company recently shared promising interim Phase 1b data for its GBA1 program, noting that all 16 patients in Part 2 completed five months of treatment. The results showed stable MDS-UPDRS scores, with patients reporting improvements in sensory functions and balance. Gain Therapeutics plans to incorporate protocols to further evaluate these outcomes in its upcoming Phase 2a study, scheduled to begin in the third quarter of 2026. The company also reported better-than-expected first-quarter results, surpassing analysts' loss estimates, and highlighted a strong liquidity position, which provides flexibility for its clinical programs.